Ncardia Established Following Pluriomics Axiogenesis Merger
Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings.
Ncardia has secured an additional €4.25M from existing investors, Vesalius Biocapital, SFPI-FPIM and Sambrinvest as a direct result of the merger. Both scientific specialists & business units based in the Netherlands, Germany, Belgium and the US are focused on meeting the needs of customers in pharma and biotech sectors and have developed a pipeline of innovative products, services and solutions to position Ncardia as the trusted global leader in hiPSC based cardiac drug discovery & development. Dr. Stefan Braam, Pluriomics co-founder has been appointed CEO while Dr. Heribert Bohlen, Axiogenesis co-founder has been named CSO. Dr. Bernd Fronhoff will become COO.
“Establishing Ncardia was a strategic decision” said Stefan Braam CEO. “We are bringing the best of both organisations together – our people, products, services, industry knowledge and expertise to develop and generate more innovative stem cell based products and services to serve our customers at an even higher level than before. Our goal is to be the trusted global leader in the hiPSC drug discovery and development field so that Ncardia is the partner of choice for scientists operating in cardiovascular and neural safety and efficacy projects.”
By joining forces, Ncardia can provide assay solutions in a shorter time-frame which will help to accelerate and improve the discovery & development of efficient and safe drugs. The combined business allows Ncardia to build on over two decades of knowledge, stem cell product R&D and commercialization by Pluriomics and Axiogenesis respectively. It gives Ncardia further opportunities for growth in a rapidly developing marketplace.
Heribert Bohlen CSO added, “Combining the scientific excellence and expertise of Pluriomics and Axiogenesis boosts our R&D capabilities. It allows us to accelerate innovations within the cardiac drug discovery & development areas. He went on to say that “the combined specialist units will allow our customers to accelerate and improve drug candidate selection, lower costs, and ultimately increase drug development efficiency.“
Ncardia has more than 60 employees in Europe and the US. The combined teams will continue to engage with clients to develop and provide customers with a broad portfolio of cardiovascular cell models and services. These services range from disease modelling to cardiovascular drug efficacy screening to cardiac safety assessment and implementing Ncardia’s innovative and proprietary cell types in various screening platforms.
For more information visit www.Ncardia.com or contact:
Ncardia (www.ncardia.com) believes that stem cell technology will help to get better medicines to patients faster. The company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®) as well cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the CardioplateTM product line of quality controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS4U, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®.
Ncardia is committed to deliver its clients working assays solutions through in house assay development and extensive support. The company has a wide range of supported applications and compound assay services such as of electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology and toxicology testing. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening.
Ncardia is based in Belgium, The Netherlands, Germany and in the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.
Celine Hechard, PhD
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 13:49 | Tiedote
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41 | Tiedote
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42 | Tiedote
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00 | Tiedote
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07 | Tiedote
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme